Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470029 | 0.85 | — | — | |
| SCHEMBL8886026 | 0.78 | PNP (0.35) | PNPPARP1 | |
| SCHEMBL1828928 | 0.77 | PNP (0.34) | PNPPARP1 | |
| SCHEMBL20576 | 0.77 | PNP (0.34) | PNPPARP1 | |
| SCHEMBL2051359 | 0.77 | PNP (0.34) | PNPPARP1 | |
| SCHEMBL6168437 | 0.77 | PNP (0.34) | PNPPARP1 | |
| SCHEMBL20866 | 0.77 | ATAD2 (0.41) | PNP | |
| SCHEMBL9960806 | 0.75 | PNP (0.38) | PNPPARP1 | |
| SCHEMBL7812591 | 0.74 | ABL1 (0.33) | PNPPARP1 | |
| SCHEMBL10597939 | 0.74 | PNP (0.33) | PNPPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146475-A2 | METHOD FOR DETERMINING GENOTOXICITY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-08-03 | — | — | WO | disclosed |
| US-8597900-B2 | Compositions and methods for the treatment of cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130280258-A1 | PROGNOSTIC, DIAGNOSTIC, AND CANCER THERAPEUTIC USES OF FANCI AND FANCI MODULATING AGENTS | MILTENYI BIOTEC GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-8541192-B2 | Methods to identify USP1 deubiquitinating enzyme complex inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541198-B2 | Method for determination and quantification of radiation or genotoxin exposure | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110312514-A1 | Method For Determination And Quantification Of Radiation Or Genotoxin Exposure | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110269817-A1 | COMPOSITIONS AND METHODS RELATED TO SIRT1 FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110151487-A1 | Compositions And Methods For The Treatment Of Cancer | DANA-FARBER CANCER INSTITUTE, INC. | 2011-06-23 | — | — | US | disclosed |
| EP-2315600-A2 | COMPOSITIONS AND METHODS RELATED TO SIRT1 FUNCTION | The Regents of the University of California (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7910325-B2 | Screening agents which modulate formation of Fanconi anemia complementation group D2 (FANC D2) -containing foci; cell expressing polynucleotide comprising DNA sequence encoding protein; determining a subject's sensitivity to a genotoxic agent | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-0517413-B1 | Fermentation of a triol heptanoic acid by mutant strains of aspergillus terreus | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5470729-A | Method of isolating restriction fragment deletions in Vibrio cholerae, and products thereof | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0119031-B1 | Avirulent Vibrio Cholerae and methods for its production | UNIV MARYLAND (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0581329-A1 | Method of isolating restriction fragment deletions in vibrio cholerae, and products thereof | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5250435-A | Fermentation culture which produces high yields of pure reductase inhibitors or anticholesterol agents | MERCK & CO., INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0485591-A4 | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN -I(VIBRIO CHOLERAE), AND PRODUCTS THEREOF | — | 1993-07-14 | — | — | EP | disclosed |
| EP-0517413-A1 | Fermentation of a triol heptanoic acid by mutant strains of aspergillus terreus | MERCK & CO. INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| US-5135862-A | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN VIBRIO CHOLERAE, PRODUCTS THEREOF | UNIVERSITY OF MARYLAND (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0485591-A1 | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN -i(VIBRIO CHOLERAE), AND PRODUCTS THEREOF. | UNIV MARYLAND (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991018979-A1 | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN VIBRIO CHOLERAE, AND PRODUCTS THEREOF | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269817-A1 | COMPOSITIONS AND METHODS RELATED TO SIRT1 FUNCTION | CRY1, PER2, SIRT1 | PNP 3131/4885PARP1 930/4885 |
| US-20130280258-A1 | PROGNOSTIC, DIAGNOSTIC, AND CANCER THERAPEUTIC USES OF FANCI AND FANCI MODULATING AGENTS | FANCI, FANCF, FANCD2 | PNP 2237/4885PARP1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.